Insights
Search Results
Client Highlights
7.08.26
Wilson Sonsini Advises Insilico on Collaboration with Takeda
On July 1, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence and automation, announced a strategic collaboration agreement with Takeda to use Insilico’s proprietary end-to-end platform, Pharma.AI, to advance drug candidates across various therapeutic areas, with a potential initial value of $600 million. Insilico will lead drug discovery, while Takeda will further development, including advancing candidates past clinical trials.
Client Highlights
6.22.26
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
6.03.26
Wilson Sonsini Advises Luminopia on Licensing Agreement with ROHTO
On June 2, 2026, Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Luminopia on the transaction.
Client Highlights
4.09.26
Firm Advises Marvell Technology on Strategic Partnership and $2 Billion Investment from NVIDIA
On March 31, 2026, NVIDIA announced it has invested $2 billion in Marvell Technology as part of a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™. This partnership offers customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The companies will also collaborate on silicon photonics technology. Wilson Sonsini Goodrich & Rosati advised Marvell on the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Insilico on Global R&D Collaboration with Lilly
On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
3.25.26
Wilson Sonsini Advises Nosis Bio on Strategic Collaboration and License Agreement with Johnson & Johnson
On March 24, 2026, Nosis Bio, a pioneer in AI-enabled cell-specific delivery for RNA medicines, announced an expansion of its strategic collaboration with Johnson & Johnson. Their initial collaboration has been expanded through an option exercise, and simultaneously, Nosis Bio and Johnson & Johnson have entered into a new strategic collaboration agreement focused on neurology. The collaborations will deploy Nosis’ Connexa™ platform, which combines a proprietary atlas of cell-specific internalizing receptor targets with physics-aware generative AI, to design delivery vehicles that can navigate complex cell types. Wilson Sonsini Goodrich & Rosati advised Nosis Bio on the transaction.
Client Highlights
3.18.26
Wilson Sonsini Advises XENOM on $15 Million Seed Round and Commercial Agreement with Rogue Fitness
On February 27, 2026, XENOM announced it has officially launched with a $15 million seed financing to create stadium-scale global events. The round was led by WndrCo and Rogue Fitness. Additionally, Rogue Fitness will serve as XENOM’s official equipment supplier. Wilson Sonsini Goodrich & Rosati advised XENOM on the transactions.
Client Highlights
3.13.26
Wilson Sonsini Advises Enodia Therapeutics on Purchase Agreement with Kezar Life Sciences
On March 12, 2026, Enodia Therapeutics (Enodia), a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. Under the terms of the purchase agreement between Enodia and Kezar, Kezar will receive an initial upfront payment totaling $1 million, and will receive future payments upon achievement of certain development, regulatory and commercialization milestones, for a potential total of up to $127 million. Enodia has also agreed to pay tiered royalties on net sales. Wilson Sonsini Goodrich & Rosati advised Enodia on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Taggstar on Acquisition by Syndigo
On March 10, 2026, Syndigo, a global leader in product experience management, announced it has acquired Taggstar, a leading AI-powered conversion rate optimization platform for digital commerce. The acquisition expands Syndigo’s product experience cloud by incorporating social proof messaging, attribute messaging and dynamic badging. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Taggstar on the transaction.